Review: Aldosterone blockade reduces mortality in patients with left ventricular dysfunction

Liu, Peter; Ezekowitz, J. A.
August 2009
ACP Journal Club;8/18/2009, Vol. 151 Issue 2, p7
Academic Journal
The article reports that aldosterone blockade reduces mortality in patients with left ventricular dysfunction and heart failure or post myocardial infarction but is associated with adverse renal and electrolyte abnormalities. With appropriate monitoring, the benefits seen in these trials should translate into real-life practice.


Related Articles

  • Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. Pitt, Bertram; Remme, Willem; Zannad, Faiez; Neaton, James; Martinez, Felipe; Roniker, Barbara; Bittman, Richard; Hurley, Steve; Kleiman, Jay; Gatlin, Marjorie // New England Journal of Medicine;4/3/2003, Vol. 348 Issue 14, p1309 

    Background: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial...

  • EMPHASIS-HF: Eplerenone reduced death, hospitalization by 37% in systolic HF. Ellis, Brian; Fisher, Stacey L.; Kalvaitis, Katie // Cardiology Today;Dec2010, Vol. 13 Issue 12, p13 

    The article reports that the EMPHASIS-HF trial has revealed a 37% reduction in the risk of death or hospitalization among patients with systolic heart failure (HF) who received eplerenone.

  • Angioplasty prolongs survival in high risk patients with confirmed heart attack.  // BMJ: British Medical Journal (International Edition);12/17/2005, Vol. 331 Issue 7530, Preceding p1417 

    The article looks at the question of whether or not angioplasty can reduce overall mortality compared with fibrinolysis in patients with heart attack. According to recent research, primary angioplasty reduces overall mortality among persons identified as high risk by the trombolysis in...

  • The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy. Sica, Domenic A. // Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71 

    Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono-...

  • Heart failure. Clark, Andrew L. // Archivos de Cardiología de México;oct-dic2011, Vol. 81 Issue 4, p383 

    No abstract available.

  • Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Zannad, Faiez; McMurray, John J.V.; Drexler, Helmut; Krum, Henry; van Veldhuisen, Dirk J.; Swedberg, Karl; Shi, Harry; Vincent, John; Pitt, Bertram // European Journal of Heart Failure;Jun2010, Vol. 12 Issue 6, p617 

    Aims: In chronic heart failure (HF), aldosterone antagonists have been shown to improve survival in patients with low ejection fraction and moderate-to-severe symptoms [New York Heart Association (NYHA) classes III and IV]. Efficacy of these agents was also shown when they were administered to...

  • Aldosterone use in heart failure.  // Infectious Disease Alert;Dec2009 Pharmacology Watch Suppleme, p1 

    The article discusses research on the clinical use of aldosterone for heart failure (HF). It references a study published in the 2009 issue of the "Journal of the American Medical Association." The study included 43,000 patients who were hospitalized due to HF between 2005 and 2007. Study...

  • Prognostic Value of Total Cholesterol in the Elderly. Wellbery, Caroline // American Family Physician;3/1/2004, Vol. 69 Issue 5, p1235 

    Discusses research being done on the prognostic value of total cholesterol level measured in elderly survivors of acute myocardial infarction. Reference to study by J. M. Foody and colleagues, published in the July 2003 issue of the "Journal of American Society"; Association between cholesterol...

  • Inspra.  // Formulary;Nov2002, Vol. 37 Issue 11, p553 

    Focuses on Pharmacia & Upjohn Inc.'s aldosterone blocker Inspra, generic name eplerenone. Use of Inspra for treating hypertension; Effectiveness and safety of the drug; Recommended dosage.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics